American Research & Management Company’s Acadia Pharmaceuticals ACAD Stock Holding History

American Research & Management Company’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2K	Hold	100	–	–	﹤0.01%	374
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	374
2022 Q1	$2K	Hold	100	–	–	﹤0.01%	373
2021 Q4	$2K	Hold	100	–	–	﹤0.01%	360
2021 Q3	$2K	Hold	100	–	–	﹤0.01%	352
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	359
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	339
2020 Q4	$5K	Hold	100	–	–	﹤0.01%	322
2020 Q3	$4K	Hold	100	–	–	﹤0.01%	303
2020 Q2	$5K	Hold	100	–	–	﹤0.01%	290
2020 Q1	$4K	Hold	100	–	–	﹤0.01%	283
2019 Q4	$4K	Hold	100	–	–	﹤0.01%	299
2019 Q3	$4K	Hold	100	–	–	﹤0.01%	303
2019 Q2	$3K	Hold	100	–	–	﹤0.01%	323
2019 Q1	$3K	Hold	100	–	–	﹤0.01%	356
2018 Q4	$2K	Hold	100	–	–	﹤0.01%	316
2018 Q3	$2K	Hold	100	–	–	﹤0.01%	327
2018 Q2	$2K	Hold	100	–	–	﹤0.01%	310
2018 Q1	$2K	Hold	100	–	–	﹤0.01%	346
2017 Q4	$3K	Hold	100	–	–	﹤0.01%	344
2017 Q3	$4K	Hold	100	–	–	﹤0.01%	309
2017 Q2	$3K	Hold	100	–	–	﹤0.01%	311
2017 Q1	$3K	Hold	100	–	–	﹤0.01%	302
2016 Q4	$3K	Hold	100	–	–	﹤0.01%	319
2016 Q3	$3K	Hold	100	–	–	﹤0.01%	330
2016 Q2	$3K	Hold	100	–	–	﹤0.01%	315
2016 Q1	$3K	Buy	+100	New	+$2.18K	﹤0.01%	327

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

American Research & Management Company's ACAD Position: Q3 2022 in Review

American Research & Management Company held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2022 at 100 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #374.

American Research & Management Company first reported a position in ACAD in Q1 2016 and has held it in 27 quarters since. The position peaked at $5K in Q4 2020. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

American Research & Management Company held 100 shares of Acadia Pharmaceuticals worth $2K as of Q3 2022.
American Research & Management Company left its Acadia Pharmaceuticals share count unchanged in Q3 2022.
Acadia Pharmaceuticals made up ﹤0.01% of American Research & Management Company's portfolio in Q3 2022, its #374 holding.
American Research & Management Company first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 27 quarters since.
American Research & Management Company's Acadia Pharmaceuticals position peaked at $5K in Q4 2020.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.